Novavax, Inc [NVAX] stock is trading at $8.43, up 0.60%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NVAX shares have gain 0.84% over the last week, with a monthly amount drifted -11.26%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On August 20, 2025, downgrade downgraded it’s rating to Underperform but maintained its price target of $7 on the stock. Citigroup started tracking the stock assigning a Sell rating and suggested a price target of $6 on June 17, 2025. BTIG Research initiated its recommendation with a Buy and recommended $19 as its price target on February 28, 2025. JP Morgan downgraded its rating to Underweight for this stock on July 30, 2024, but kept the price target unchanged to $8. In a note dated May 10, 2024, JP Morgan upgraded an Neutral rating on this stock.
Novavax, Inc [NVAX] stock has fluctuated between $5.01 and $11.55 over the past year. Currently, Wall Street analysts expect the stock to reach $14.5 within the next 12 months. Novavax, Inc [NASDAQ: NVAX] shares were valued at $8.43 at the most recent close of the market. An investor can expect a potential return of 72.0% based on the average NVAX price forecast.
Analyzing the NVAX fundamentals
Novavax, Inc [NASDAQ:NVAX] reported sales of 1.08B for the trailing twelve months, which represents a drop of -42.42%. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at 0.33%, Pretax Profit Margin comes in at 0.4%, and Net Profit Margin reading is 0.39%. To continue investigating profitability, this company’s Return on Assets is posted at 0.32, Equity is -1.42 and Total Capital is 0.38. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 6.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.23 points at the first support level, and at 8.04 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.64, and for the 2nd resistance point, it is at 8.86.
Ratios To Look Out For
For context, Novavax, Inc’s Current Ratio is 2.36. Also, the Quick Ratio is 2.34, while the Cash Ratio stands at 0.68. Considering the valuation of this stock, the price to sales ratio is 1.27, the price to book ratio is 36.33 and price to earnings (TTM) ratio is 3.73.
Transactions by insiders
Recent insider trading involved YOUNG JAMES F, Former Director, that happened on May 19 ’25 when 10000.0 shares were purchased. Former Director, YOUNG JAMES F completed a deal on Apr 14 ’25 to buy 4000.0 shares. Meanwhile, Director King Rachel K. sold 4150.0 shares on Dec 13 ’24.
